A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients with Androgen Receptor (Ar)-Expressing Metastatic Breast Cancer (MBC).

Denise A. Yardley,Robyn R. Young,Kerin B. Adelson,Andrea L. Silber,Jose E. Najera,Davey B. Daniel,Nancy Peacock,Lindsey Finney, Susan J. Hoekstra,Mythili Shastry,John D. Hainsworth,Howard A. Burris

Cancer Research（2022）SCI 1区

Sarah Cannon Res Inst | Ctr Canc & Blood Disorders | Yale Sch Med | Canc Ctr Southwest Oklahoma

Cited 4|Views30

Abstract

Treatment with orteronel had no significant activity in patients with refractory AR + MBC selected using an IHC AR staining threshold of >= 10%. Further development of orteronel in MBC is not recommended. Further efforts to validate the AR as a therapeutic target should focus on identifying new markers predictive of sensitivity to AR-targeted agents. Background: AR is a targetable pathway with AR modulation inhibiting estrogen- and androgen-mediated cell proliferation. Orteronel is an oral, selective, nonsteroidal inhibitor of 17, 20-lyase, a key enzyme in androgen biosynthesis. This study evaluated single-agent orteronel in AR+ metastatic breast cancer (MBC). Methods: Male/female patients with AR+ MBC were grouped in Cohort 1: AR+ TNBC with 1-3 prior chemotherapy regimens or Cohort 2: AR+ HR+ (estrogen [ER +]/ progesterone receptor [PR+] positive) HER2+/- with 1 to 3 prior hormonal and at least 1 prior chemotherapy regimen. Patients with HER2+ MBC must have received at least 2 lines of HER2-targeted therapy. Orteronel was administered at 300 mg BID; response rate was the primary endpoint. Results: Seventy patients were enrolled (Cohort 1, n = 26 and Cohort 2, n = 44). Median treatment duration was 7.1 weeks. Seven patients were on treatment for >= 6 months. One of the 21 evaluated patients in Cohort 1 (4.8%) had an objective response. In Cohort 2, none of the first 23 patients to be evaluated had a response and accrual was stopped. Median progression-free and overall survival were 1.8 and 8.3 months, respectively. Toxicities were predominantly Grade 1 or 2 nausea/vomiting (36%) and fatigue (31%). Grade 3 or 4 events in >= 5% of patients included increased amylase/lipase (10%) and hypertension (6%). Conclusions: Orteronel demonstrated limited clinical activity in heavily pre-treated AR+ MBC. Further development of orteronel in MBC is not recommended. Further efforts to validate the AR as a therapeutic target should focus on identifying new markers predictive of sensitivity to AR-targeted agents. (C) 2021 Published by Elsevier Inc.

Translated text

Key words

Triple-negative breast cancer (TNBC),HR+/HER2-,Orteronel,Androgen receptor,Metastatic breast cancer

求助PDF

上传PDF

Bibtex

AI Read Science

AI Summary

AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.

Example

Background

Key content

Introduction

Methods

Results

Related work

Fund

Key content

Pretraining has recently greatly promoted the development of natural language processing (NLP)
We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance

Upload PDF to Generate Summary

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper